{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '5.6.2 Definition of Serious Adverse Events (SAEs)', 'An AE is considered \"serious\" if, in the view of either the investigator or sponsor, it results in', 'any of the following outcomes:', 'Results in death', 'Is life-threatening (an AE is considered \"life-threatening\" if, in the view of either the', 'investigator or sponsor, its occurrence places the subject at immediate risk of death. It', 'does not include an AE that, had it occurred in a more severe form, might have caused', 'death)', 'Results in persistent or significant disability/incapacity or substantial disruption of the', 'ability to conduct normal life functions', 'Results in congenital anomaly, or birth defect', 'Requires inpatient hospitalization (except for planned procedures as allowed per study)', 'or leads to prolongation of hospitalization (except if prolongation of planned', 'hospitalization is not caused by an AE). Hospitalization for', 'treatment/observation/examination caused by AE is to be considered as serious.)', 'Other medically important events (defined in paragraph below)', 'Medical and scientific judgment should be exercised in deciding whether expedited reporting', 'is appropriate in other situations, such as important medical events that may not be', 'immediately life-threatening or result in death or hospitalization but may jeopardize the', 'subject or may require intervention to prevent one of the other outcomes listed in the', 'definition above. These events, including those that may result in disability/incapacity', 'usually are considered serious. Examples of such events are intensive treatment in an', 'emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that', 'do not result in hospitalization; or development of drug dependency or drug abuse.', 'The sponsor has a list of events that they classify as \"always serious\" events. If an AE is', 'reported that is considered to be an event per this classification as \"always serious\",', 'additional information on the event may be requested.', '5.6.3 Criteria for Causal Relationship to Study Drug', 'The investigator is obligated to assess the relationship between the study drug and each', 'occurrence of each (S)AE. The investigator will use clinical judgment to determine the', \"relationship. The investigator should also use the Investigator's Brochure (IB) and/or Product\", 'Information, for marketed products. The investigator is requested to provide an explanation', 'for the causality assessment for each SAE and must document this on the SAE worksheet.', 'The causality assessment is one of the criteria used when determining regulatory reporting', 'requirements. The investigator may revise his/her assessment of causality in light of new', 'information regarding the SAE and shall send an SAE follow-up report and update the eCRF', 'with the new information and updated causality assessment.', 'Following a review of the relevant data, the causal relationship between the study drug and', 'each (S)AE will be assessed by answering \"yes\\' or \\'no\\' to the question \"Do you consider', '14 Sep 2020', 'Astellas', 'Page 73 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'that there is a reasonable possibility that the event may have been caused by the study', 'drug\".', 'When making an assessment of causality, the following factors are to be considered when', 'deciding if there is evidence and/or arguments to suggest there is a \"reasonable possibility\\'', 'that an (S)AE may have been caused by the study drug (rather than a relationship cannot be', 'ruled out) or if there is evidence to reasonably deny a causal relationship:', 'Plausible temporal relationship between exposure to the study drug and (S)AE onset', 'and/or resolution. Has the subject actually received the study drug? Did the (S)AE occur', 'in a reasonable temporal relationship to the administration of the study drug?', 'Plausibility; i.e., could the event been caused by the study drug? Consider biologic', 'and/or pharmacologic mechanism, half-life, literature evidence, drug class, preclinical', 'and clinical study data, etc.', 'Dechallenge/Dose reduction/Rechallenge:', 'Did the (S)AE resolve or improve after stopping or reducing the dose of the suspect', 'drug? Also consider the impact of treatment for the event when evaluating a', 'dechallenge experience.', 'Did the (S)AE reoccur if the suspected drug was reintroduced after having been', 'stopped?', 'Laboratory or other test results; a specific lab investigation supports the assessment of', 'the relationship between the (S)AE and the study drug (e.g., based on values pre-, during', 'and post-treatment)', 'Available alternative explanations independent of study drug exposure; such as other', 'concomitant drugs, past medical history, concurrent or underlying disease, risk factors', 'including medical and family history, season, location, etc. and strength of the alternative', 'explanation', 'There may be situations in which an SAE has occurred and the investigator has minimal', 'information to include in the initial report to the sponsor. However, it is very important that', 'the investigator always make an assessment of causality for every event before the initial', 'transmission of the SAE data to the sponsor. With limited or insufficient information about', 'the event to make an informed judgment and in absence of any indication or evidence to', 'establish a causal relationship, a causality assessment of \"no\\' is to be considered. In such', 'instance, the investigator is expected to obtain additional information regarding the event as', 'soon as possible and to re-evaluate the causality upon receipt of additional information.', '5.6.4 Criteria for Defining the Severity of an Adverse Event', 'AEs, including abnormal clinical laboratory values, will be graded using the NCI-CTCAE', 'guidelines (Version 4.03). The items that are not stipulated in the NCI-CTCAE Version 4.03', 'will be assessed according to the criteria below and entered into the eCRF.', '14 Sep 2020', 'Astellas', 'Page 74 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}